Brokerages forecast that Karyopharm Therapeutics Inc. (NASDAQ:KPTI – Get Rating) will announce sales of $36.38 million for the current quarter, Zacks Investment Research reports. Six analysts have made estimates for Karyopharm Therapeutics’ earnings. The highest sales estimate is $38.14 million and the lowest is $34.26 million. Karyopharm Therapeutics posted sales of $22.60 million in the same quarter last year, which would indicate a positive year-over-year growth rate of 61%. The business is scheduled to announce its next quarterly earnings results on Monday, January 1st.
On average, analysts expect that Karyopharm Therapeutics will report full year sales of $164.20 million for the current year, with estimates ranging from $143.92 million to $182.78 million. For the next year, analysts forecast that the company will post sales of $193.85 million, with estimates ranging from $162.36 million to $238.77 million. Zacks Investment Research’s sales calculations are an average based on a survey of research firms that cover Karyopharm Therapeutics.
Karyopharm Therapeutics (NASDAQ:KPTI – Get Rating) last issued its quarterly earnings data on Thursday, May 5th. The company reported ($0.53) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.63) by $0.10. During the same period last year, the company earned ($0.77) EPS.
Shares of Karyopharm Therapeutics stock opened at $5.21 on Thursday. Karyopharm Therapeutics has a 1 year low of $4.42 and a 1 year high of $14.73. The company has a market capitalization of $413.77 million, a P/E ratio of -3.54 and a beta of -0.16. The business has a 50 day moving average price of $6.94 and a 200 day moving average price of $7.63.
Several hedge funds and other institutional investors have recently made changes to their positions in the company. Aaron Wealth Advisors LLC purchased a new stake in Karyopharm Therapeutics during the 1st quarter worth $385,000. Marshall Wace LLP purchased a new stake in Karyopharm Therapeutics during the 4th quarter worth $57,000. Zurcher Kantonalbank Zurich Cantonalbank boosted its position in Karyopharm Therapeutics by 78.0% during the 1st quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 10,641 shares of the company’s stock worth $78,000 after purchasing an additional 4,664 shares during the period. Point72 Hong Kong Ltd purchased a new position in Karyopharm Therapeutics in the 3rd quarter valued at about $63,000. Finally, American Trust purchased a new position in Karyopharm Therapeutics in the 4th quarter valued at about $81,000. 67.75% of the stock is owned by institutional investors.
Karyopharm Therapeutics Company Profile (Get Rating)
Karyopharm Therapeutics Inc, a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases. The company discovers, develops, and commercializes novel and Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and inhibiting the nuclear export protein XPO1.
- Get a free copy of the StockNews.com research report on Karyopharm Therapeutics (KPTI)
- Wendy’s Growth Story Has Come To An End
- Beyond Meat Could Sizzle After Q1 Results Are Released
- Can Six Flags(SIX) or Cedar Fair (FUN) Give Investors a Thrill Later This Year?
- Is Now The Time To Buy Coinbase (NASDAQ: COIN)?
- Inflation Hasn’t Peaked At Reynolds Consumer Products
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Karyopharm Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Karyopharm Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.